All In Biotech

Drug Trial Radar · NCT03246529

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Actual

Start

Mar 23, 2018

Primary completion

Dec 22, 2020

Study completion Sep 30, 2029

Sponsor

Lead sponsor
BioLineRx, Ltd.Industry
Sponsor type
Industry
First posted
Aug 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

Conditions

  • Multiple Myeloma

Interventions

  • BL-8040 1.25 mg/kg + G-CSFDrug

    Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care

  • Placebo +G-CSFDrug

    Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis SessionsTime frame: From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • University of Florida

    Gainesville, Florida

  • University of Miami

    Miami, Florida

  • Loyola University Medical Center

    Chicago, Illinois

  • University of Maryland

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • The Washington University School of Medicine

    St Louis, Missouri

  • University of Cincinnati

    Cincinnati, Ohio

  • MD Anderson Cancer Center

    Houston Texas, Texas

  • Huntsman Cancer Institute in University of Utah

    Salt Lake City, Utah

  • University of Koln

    Cologne, Koln, Germany

  • Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases

    Budapest, Hungary

  • University of Debrecen

    Debrecen, Hungary

  • Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele

    Catania, Italy

  • Presidio Ospedaliero Morelli Viale Europa

    Reggio Calabria, Italy

  • Hospital de La Santa Creu I Sant Pau

    Barcelona, Spain

  • Hospital University Ramon y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.